ARKG:ARCA-ARK Genomic Revolution Multi-Sector (USD)

ETF | Health | NYSE Arca

Last Closing

USD 28.55

Change

+0.65 (+2.33)%

Market Cap

USD 1.61B

Volume

1.13M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Inception Date: 30/10/2014

Primary Benchmark: NASDAQ Health Care GR EUR

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.9%

Management Expense Ratio: 0.75 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Health

ETFs Containing ARKG

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.98% 100% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.98% 100% F 2% F
Trailing 12 Months  
Capital Gain -1.18% 100% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.18% 100% F 5% F
Trailing 5 Years  
Capital Gain -13.17% 100% F 18% F
Dividend Return 6.77% 100% F 29% F
Total Return -6.40% 100% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain 19.45% 100% F 96% N/A
Dividend Return 20.61% 100% F 96% N/A
Total Return 1.15% 100% F 50% F
Risk Return Profile  
Volatility (Standard Deviation) 77.75% 100% F 2% F
Risk Adjusted Return 26.51% 100% F 42% F
Market Capitalization 1.61B 100% F 89% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike